MORPHOLOGICAL CHARACTERISTIC OF MYOCARDIUM IN EXPERIMENTAL STREPTOZOTOCIN DIABETES MELLITUS AND ITS CORRECTION

Vlasiuk T. I.

MORPHOLOGY

Scentific article

The aim of the study is to determine the morphological changes of myocardium of rats with experimental streptozotocin diabetes mellitus and its correction. 19 mature male Wistar rats (weighing 200-220 g) were used for the study. Animals were divided into 3 groups: 1 – intact (5 animals), 2 – 5 animals with experimental diabetes mellitus (EDM), 3 – 9 animals from the EDM who received antidiabetic therapy. EDM in rats of the 2nd and 3rd groups was modelled by a single intraperitoneal injection of streptozotocin (Sigma, USA) at a dose of 6 mg/100 g of body weight pre-diluted in 0.1 M citrate buffer pH 4.5. Animals of the 3rd group from the 14th day of the development of the EDM were receiving antidiabetic therapy: 3a subgroup (3 animals) were receiving exenatide (“Baeta”, EliLilli, USA) at a dose of 0.04 μg / 100 g / day subcutaneously in the morning; Subgroup 3b (3 animals) were receiving subcutaneous injections of insulin glargine (“LantusSoloStar”) at a dose of 1-3 U / kg body weight / day subcutaneously in the morning followed by titration according to the level of glucose in the blood; 3c subgroup was receiving subcutaneous injections of insulin glargine in the morning at a dose of 1-3 U / kg of body weight per day followed by titration according to the level of glucose in the blood, and in the evening – exenatide (0.02 μg / 100 g / day subcutaneously, 30 minutes before feeding. The pieces of myocardium of the right and left ventricles of the heart were taken on the 28th day of the experiment. Histologic (coloring of hematoxylin and eosin) and electron microscopic research methods were used. The initial signs of diabetic cardiomyopathy were detected on the 28th day of experimental diabetes mellitus. In the 3rd group, in which animals were receiving different treatment, the best glycemic parameters were observed in the 3c subgroup of rats, which were receiving combined treatment, while the highest levels of glucose and glycosylated hemoglobin were in the 3a subgroup of animals, receiving only injections of exenatide. Most of the cardiomyocytes of 3c subgroup of rats in the lightoptical and ultrastructural organization did not differ from those in intact rats. Daily injections of exenatide and insulin result in: normalization of glucose and glycosylated hemoglobin levels in the blood, repair of morphometric parameters and ultrastructural structure of cardiomyocytes of the ventricles of the heart.

diabetes mellitus, myocardium, rats, insulin, exenatide

1. Tron`ko MD. Analiz, priorytety, shlyaxy vykonannya derzhavnoyi cilovoyi programy “Czukrovyj diabet” na 2009-2013 roky. Zdorovya Ukrayiny. Tematychnyj nomer. 2010:16-7. [in Ukrainian].
2. Kuzyshyn OV, Kovalyshyn NV, Almashyna XV. Bioxemiya czukrovogo diabetu: 1. Teoretychna chastyna (oglyad). Medychna xemiya. 2010;10:74115. [in Ukrainian].
3. Konstantinos Trachanas, sKevos Sideris, Constantina Aggeli, Emmanouil PoulidaKis, Konstantinos Gatzoulis, Dimitrios Tousoulis, et al. Diabetic Cardiomyopathy: From Pathophysiology to Treatment Hellenic. J Cardiol. 2014;55:411-21.
4. Kixtyak OP. Vplyv suputnoyi terapiyi nevrologichnyx i sercevo-sudynnyx urazhen u hvoryh na czukrovyj diabet 2 typu. Zdorovya Ukrayiny. 2017;1:18-20. [in Ukrainian].
5. Kaminskyj OV. Chomu zrostaye kilkist pryznachen preparativ metforminu dlya likuvannya czukrovogo diabetu 1 typu? Zdorovya Ukrayiny. 2017;23(420):3. [in Ukrainian].
6. Mankovskyj BN. Novosty ezhegodnogo kongressa Evropejskoj assocyacyy po yzuchenyyu dyabeta. Zdorovya Ukrayiny. 2017;3(39):14-5. [in Russiаn].
7. Korsak YuV. Statevi ta vikovi osoblyvosti urazhennya miokarda u hvoryh na czukrovyj diabet 2 typu v poyednanni z ishemichnoyu hvoroboyu sercya. Ukrayinskyj terapevtychnyj zhurnal. 2006;3:46. [in Ukrainian].
8. Barinov EF, Sulayeva YeM, Kanana YeM. Strukturni determinanty rozvytku dylatacijnoyi kardiomiopatiyi pry eksperymentalnomu czukrovomu diabeti. Klinichna anatomiya ta operatyvna xirurgiya. 2009;8(1):26-32. [in Ukrainian].
9. Ashish A, Wilson Tang WH, Sameer Bansilal, Mario J. Garcia, Michael E. Farkouh. Diabetic Cardiomyopathy: Insights into Pathogenesis, Diagnostic Challenges, and Therapeutic Options. The American Journal of Medicine. 2008;121:748-57.
10. Cagalinec M, Waczulikova I, Ulicna, Chorvat D JR. Morphology and Contractility of Cardiac Myocytes in Early Stages of Streptozotocin-Induced Diabetes Mellitus in Rats. Physiol. Res. 2013;62:489-501.
11. Guanghong Jia, Vincent G. DeMarco, James R. Sowers. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinology. 2016;12(3):144-53.
12. Chowdhry MF, Hunaid A. Vohra, Galinanes M. Diabetes increases apoptosis and necrosis in both ischemic and nonischemic human myocardium: Role of caspases and poly-adenosine diphosphate-ribose polymerase. The Journal of Thoracic and Cardiovascular Surgery. 2007;134:124-31.
13. Boudina S, Heiko B, Sena S, Brian T. O’Neill, Vlad G. Zaha. Contribution of Impaired Myocardial Insulin Signaling to Mitochondrial Dysfunction and Oxidative Stress in the Heart. Circulation. 2009;119:1272-83.
14. Aragno M, Mastrocola R, Medana C, Catalano MG, Vercellinatto I, Danni O, et al. Oxidative Stress-Dependent Impairment of Cardiac Specific Transcription Factors in Experimental Diabetes. Endocrinology. 2006;147(12):5967-74.
15. Zhurakivska OYa, Mykulecz` TI, Zhurakivs`kyj VM. Morfologichni zminy krovonosnogo rusla miokarda pry streptozotocynovomu czukrovomu diabeti ta jogo korekciyi. Aktual`ni problemy suchasnoyi medycyny: Visnyk Ukrayinskoyi medychnoyi stomatologichnoyi akademiyi. 2017;17;1(57):230. [in Ukrainian].

«Bulletin of problems biology and medicine» Issue 3 (145), 2018 year, 260-264 pages, index UDK 611.12+616-092.4+616.379-008.64

10.29254/2077-4214-2018-3-145-260-264